For the year ending 2025-12-31, KPTI had -$1,923K decrease in cash & cash equivalents over the period. -$75,369K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -196,039 |
| Stock-based compensation expense | 14,050 |
| Depreciation and amortization | 296 |
| Amortization of debt issuance costs and discounts | 10,546 |
| Interest expense added to debt principal | 6,258 |
| Net amortization of premiums and discounts on investments | 410 |
| Loss (gain) on extinguishment of debt | -62,365 |
| Change in fair value of embedded derivatives and common stock warrants | 707 |
| Accounts receivable, net | -4,588 |
| Inventory | -701 |
| Prepaid expenses and other assets | -4,126 |
| Operating lease right-of-use assets | -1,336 |
| Accounts payable | -1,104 |
| Accrued expenses and other liabilities | 19,063 |
| Operating lease liabilities | -438 |
| Net cash used in operating activities | -75,369 |
| Proceeds from maturities of investments | 43,378 |
| Purchases of investments | 0 |
| Purchases of property and equipment | 0 |
| Net cash provided by investing activities | 43,378 |
| Proceeds from convertible debt | 15,000 |
| Proceeds from senior secured term loan | 12,250 |
| Proceeds from issuance of common stock and warrants in private placement offering | 8,750 |
| Proceeds from the exercise of stock options and shares issued under the employee stock purchase plan | 761 |
| Payment of convertible debt | 250 |
| Payment of deferred royalty obligation | 0 |
| Payment of debt and equity issuance costs | 6,463 |
| Net cash provided by financing activities | 30,048 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 20 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -1,923 |
| Cash and cash equivalents at beginning of period | 62,814 |
| Cash and cash equivalents at end of period | 60,891 |
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)